José, Tirzepatide and GLP-1: What the Science Actually Shows

You've heard about GLP-1, here's what tirzepatide adds on top

Imagine you've spent months reading about semaglutide, the GLP-1 medicine behind Wegovy. Then someone mentions tirzepatide and says it works differently. That distinction matters, and it's worth understanding precisely.

GLP-1 receptor agonists mimic a gut hormone released after eating. They slow how quickly food leaves the stomach, signal fullness to the brain, and nudge the pancreas to regulate insulin output. Tirzepatide does all of this, but it also activates the GIP receptor, a second gut-hormone pathway involved in appetite regulation and fat metabolism. Whether the two pathways reinforce each other or operate through independent routes is still an area of active research, but the clinical results suggest the combination produces greater average weight loss than single-pathway GLP-1 medicines alone.

A question our prescribers hear most weeks is whether the dual mechanism makes side effects worse. The honest answer is that the side-effect profile is broadly similar to other GLP-1 treatments (mostly gastrointestinal, mostly early on) but the tolerability starter dose of 2.5 mg exists precisely to give your system time to adjust before the prescriber considers moving you up. The GIP and GLP-1 receptor science behind tirzepatide is explained in more detail for anyone who wants to go deeper.

You can also read more about how tirzepatide compares within the GLP-1 class if you're weighing up your options before speaking to a clinician.

What the trial evidence actually shows for tirzepatide

The SURMOUNT-1 trial randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks, alongside reduced-calorie eating and activity guidance. At the 15 mg dose, average body-weight reduction was around 20–21%. That figure has been widely cited, and widely misunderstood. It is a mean across trial participants, not a floor or a guarantee. Individual results varied, as they do with any medicine.

In 2025, the SURMOUNT-5 trial published head-to-head data comparing tirzepatide with semaglutide 2.4 mg in adults with obesity. Tirzepatide produced greater average weight loss over the 72-week study period. The gap narrowed with the newer 7.2 mg semaglutide dose, but tirzepatide still held an advantage on average in that trial. NICE's appraisal of tirzepatide (TA1026), published in December 2024, reviewed this evidence base and recommended Mounjaro for NHS use within defined eligibility criteria.

None of this means tirzepatide is right for everyone. BMI, existing health conditions, current medicines and individual history all feed into whether a prescriber considers it suitable. The trial data tells you what happened on average in carefully selected study populations, your prescriber's job is to work out what is reasonable for you specifically. More context on the broader research picture is available on the tirzepatide GLP treatment overview page.

Eligibility, monitoring and what happens during treatment

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or 27 and above when at least one weight-related health condition is present, for example, high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Having a qualifying BMI does not by itself mean the medicine is appropriate; a prescriber reviews the full picture, including any contraindications.

Treatment begins at 2.5 mg, a tolerability dose rather than a therapeutic one. The prescriber then considers dose increases roughly every four weeks, working toward the highest dose you tolerate well. Injection sites rotate between the abdomen, thigh and upper arm. Storage is refrigerated; the exact room-temperature window for travel or short-term storage is set out in the Patient Information Leaflet, and that is the right place to check it rather than any secondary source.

Common side effects are gastrointestinal: nausea, changes in bowel habit, indigestion, burping and, for some people, fatigue or headache, particularly around dose increases. These generally ease over days to a couple of weeks as the body adjusts. Severe or persistent stomach pain that radiates to the back warrants prompt medical attention, pancreatitis is a known but infrequent risk with GLP-1 class medicines, highlighted in an MHRA Drug Safety Update in January 2026. The NHS patient information for tirzepatide, available at nhs.uk/medicines/tirzepatide, covers the full side-effect profile clearly. Any suspected reactions can be reported through the Yellow Card scheme.

For a rounded view of Mounjaro as the UK treatment (including how the consultation process works and what to expect from the KwikPen) the main Mounjaro page covers all of that in one place. If cost context is relevant to your thinking, the Mounjaro pricing page explains what a legitimate private prescription includes and why headline figures don't always tell the full story.